In the July 2000 issue of Annals of Oncology, Dr Mari and co-V workers presented the results of their meta-analysis of published randomized trials of adjuvant chemotherapy (CHT) after curative resections for gastric cancer (GC) [1] . To our knowledge three meta-analyses have been published in the past ten years on adjuvant CHT in GC [1] [2] [3] [4] and all seem to be concordant as regard the minimal benefit achieved from adjuvant CHT. Nevertheless, in our opinion, all three metaanalyses show some limits that derive mainly from a selection bias that can be pointed out and discussed.
The first meta-analysis was initially published in 1993 [2] and did not highlight a survival benefit. This paper was later criticized and updated in 1994 [3] . A slight but a statistically significant effect on survival for the treatment arm was reported, but it must be added that the inclusion criteria of this meta-analysis permitted intraperitoneal chemotherapy, immunochemotherapy, or non radical surgery.
Stricter inclusion criteria were adopted by Earle and Maroun [4] , even though their decision to exclude Asian trials probably introduced a selection bias.
In the recent meta-analysis by Mari et al.
[1], the inclusion of Alcobendas' [5] and Grau's [6] studies, which represented different data from the same trial, is somewhat questionable. We know that two year results of this Spanish trial were published in 1983 [5] , and ten year results in 1991 [7] ; we are also aware that it was updated in 1993 [6] , with an additional 63 patients given the same treatment schedule [4, 8] , We feel that this could probably explain the reported inlertrial heterogeneity that weakens the final conclusion of this meta-analysis [1] . In addition the inclusion of four other trials [9] [10] [11] [12] is questionable: in the Austrian paper [12] chemotherapy and immunochemotherapy arms were pooled together in the analysis of the trial results, while the British trials [9] [10] [11] permitted the inclusion of patients with residual disease after surgery.
Our attempt to re-examine this problem adopting the strict inclusion criteria reported by Earle and Maroun, but allowing inclusion of Asian trials, was presented at the 25th ESMO Congress in Hamburg [13] and is briefly reported here (Figure 1) . Again the statistical analysis suggests a significant advantage in survival for the adjuvant arms with a pooled odds ratio of 0.72 (95% CI: 0.62-0.84).
All the four meta-analysis probably present some additional methodological limits: the search for relevant studies was not extended to non-published trials, most of the analyzed trials were published in English, and the author of the papers were generally not contacted. Finally, even though all the four studies are in agreement about the slight benefit from adjuvant chemotherapy, their conclusions require confirmation from large randomized controlled trials (RCT): discrepancies between meta-analysises of small trials and large RCTare possible Figure I Odds ratios for treatment effect, on a logarithmic scale. [14, 15] . In conclusion, GC is still a relatively frequent disease with poor prognosis after surgery. Consequently, efforts to enroll patients in large, well conducted, randomized clinical trials should continue, in an attempt to define the most effective strategies for all stages of GC.
